| ||||
| | | | |
AMI Research Provides Q1 2009 Stock Valuation Report on NeoGenomics, Inc.
|
Key Largo, Fla. – May 8, 2009 -- AMI Research, a division of Hawk Associates, today announced that it has updated its stock research coverage of NeoGenomics, Inc. (OTCBB: NGNM) based on the company’s first quarter results. The complete 16-page report is available as a free download at the AMI Research website, http://www.amistockreports.com. NeoGenomicsspecializes in cancer genetics, flow cytometry and molecular diagnostic testing. The company's laboratories offer superior service, industry leading turnaround times and complete dedication to its clients and patients. Headquartered in Fort Myers, FL, NeoGenomics has laboratories in Nashville, TN, Irvine, CA and Fort Myers and provides diagnostic tests to pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, please visit www.neogenomics.org. About AMI Research AMI Research abides by the Best Practice Guidelines Governing Analyst and Corporate Issuer Relationships, developed by the CFA Institute in conjunction with the National Investor Relations Institute (NIRI). The cost of a one-year continuing research program is $30,000 prepaid for four research reports. AMI does not accept payment of fees in company shares. All AMI Research and Hawk Associates personnel are prohibited from trading in securities of covered companies. Neither the analyst’s compensation nor the compensation received by AMI Research is in any way related to the specific ratings or views contained in this research report. For more information, contact Frank Hawkins or Julie Marshall at 305-451-1888, email to: director@amistockreports.com or visit http://www.amistockreports.com. |
| ||||
